A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
← catalyst calendarNCT07736638 · readout ≤ 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
64estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-28 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-859
- Drug: Placebo for ABBV-859
- Drug: ABBV-859
- Drug: Placebo for ABBV-859
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to 99 Days
Maximum Observed Serum Concentration (Cmax) of ABBV-859
measured Up to 99 Days
Time to Cmax (Tmax) of ABBV-859
measured Up to 99 Days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-859
measured Up to 99 Days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-859
measured Up to 99 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-859
measured Up to 99 Days
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-859
measured Up to 99 Days
Apparent Clearance (CL/F) ABBV-859
measured Up to 99 Days
Antidrug Antibody (ADA)
measured Up to 99 Days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed